Savara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies
February 06, 2019 08:00 ET
|
Savara Inc.
AUSTIN, Texas, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on its two pivotal Phase 3 clinical studies, IMPALA and AVAIL. ...
Savara Announces Interim Results for OPTIMA Clinical Study of Molgradex for the Treatment of NTM
December 19, 2018 08:00 ET
|
Savara Inc.
AUSTIN, Texas, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced interim results from OPTIMA, a Phase 2a clinical study evaluating its...
Savara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th
November 16, 2018 08:00 ET
|
Savara Inc.
AUSTIN, Texas, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that Rob Neville, Savara’s Chief Executive Officer, will participate in a...
Savara Reports Third Quarter 2018 Financial Results and Provides Business Update
November 07, 2018 16:02 ET
|
Savara Inc.
Completed Enrollment in Two Clinical Studies of Molgradex: IMPALA, a Pivotal Phase 3 Study and OPTIMA, a Phase 2a StudyIMPALA Top Line Results Expected Q2 2019OPTIMA Interim Results Expected Q4 2018 ...
Savara Completes Enrollment in Molgradex OPTIMA Clinical Study for the Treatment of NTM
October 31, 2018 08:00 ET
|
Savara Inc.
Interim Results Expected in Q4 2018 AUSTIN, Texas, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced completion of the target enrollment...
Savara Reports Second Quarter 2018 Financial Results and Provides Positive Business Update
August 09, 2018 16:03 ET
|
Savara Inc.
Molgradex Phase 3 IMPALA study enrollment on track for completion in Q3 2018AeroVanc Phase 3 AVAIL study enrollment on track for completion in Q1 2019Molgradex Phase 2a OPTIMA study enrollment on...